Loading data for SDZXF — first visit, this takes a few seconds.
Sandoz Group AG
81.33 -7.93 (-8.88%)
- Market Cap
- $34.79B
- Volume
- 100
- Dividend yield
- 1.27%
- Next earnings date
- Feb 17, 2027
Sandoz Group AG (SDZXF) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 79.9
- Market Cap
- 34.8B
- Revenue (ttm)
- 11.7B
- Net Income (ttm)
- 646M
- 0.49
- 1.47
- 54.69
- n/a
- P/B (ttm)
- 3.89
- P/S (ttm)
- 2.98
- Earnings Date
- Feb 17, 2027
- Ask
- 84.29
- Volume
- 100
- Avg. Volume (20D)
- 522
- Open
- 81.25
- Previous Close
- 89.26
- Day's Range
- 81.25 - 81.25
- 52-Week Range
- 55.50 - 94.55
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- $1.02 (1.27%)
- Ex-Dividend Date
- Apr 13, 2026
About Sandoz Group AG
View profile →Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Sector Healthcare
IPO Date Oct 9, 2023
Employees 20,000
Stock Exchange OTC Markets OTCQX
Ticker Symbol SDZXF
Website https://www.sandoz.com